araag2/HINT huggingface dataset:
Clinical trial NCT01095003 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vinflunine plus capecitabine, capecitabine
SMILES: CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  female patients

          -  21 years of age or older

          -  histologically/cytologically confirmed carcinoma of the breast

          -  documented locally recurrent or metastatic disease not amenable to curative surgery or
             radiotherapy

          -  either one, two or three prior chemotherapy regimens

          -  prior treatments including both an anthracycline and a taxane and patient no longer
             candidate for these drugs

          -  measurable or non-measurable disease according to RECIST 1.1

          -  Karnofsky performance score of at least 70 %

          -  adequate haematological, hepatic and renal functions

          -  ECG without clinically relevant abnormality

        Exclusion Criteria:

          -  known or clinical evidence of brain metastasis or leptomeningeal involvement

          -  pulmonary lymphangitis or symptomatic pleural effusion

          -  any serious, concurrent uncontrolled medical disorder

          -  history of second primary malignancy

          -  preexisting motor/sensory peripheral neuropathy

          -  known history of HIV infection

          -  prior therapy with capecitabine and/or vinca-alkaloids

          -  history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or
             contra indication to any of these drugs

          -  known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency

          -  pregnancy or breast feeding
Clinical trial NCT00542685 (phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: pd 0332334, placebo, pd 0332334, pd 0332334
SMILES: CCC[C@@H](C)C[C@H](N)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC[C@@H](C)C[C@H](N)CC(O)=O, CCC[C@@H](C)C[C@H](N)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of GAD (Diagnostic and Statistical Manual-IV [DSM-IV], 300.02) as
             established by the clinician (psychiatrist or licensed clinical psychologist) who has
             interviewed the subject using all sources of data including the Mini International
             Neuropsychiatric Interview (MINI) for DSM-IV Axis I disorders and other clinical
             information. Subjects with specific phobia(s) (as defined in DSM-IV) or dysthymic
             disorder will be allowed in the study.

          -  Subjects must have a HAM-A total score ≥20 at the screening (V1) and randomization
             (V2) visits. Subjects must also have a Covi Anxiety Scale score of >9 and a Raskin
             Depression Scale score <7 at the Screening (V1) visit to ensure predominance of
             anxiety symptoms over depression symptoms.

        Exclusion Criteria:

          -  Subjects with evidence or history of clinically significant hematological, renal,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic,
             neurologic, active infections, immunological, or allergic disease (including drug
             allergies).

          -  Any of the following current (within the past 6 months through the present) DSM-IV
             Axis I diagnoses: Major depressive disorder, Obsessive compulsive disorder, Panic
             disorder; Agoraphobia, Posttraumatic stress disorder, Anorexia, Bulimia,
             Caffeine-induced anxiety disorder, Alcohol or substance abuse or dependence unless in
             full remission for at least 6 months, Social anxiety disorder.

          -  Any of the following past or current DSM IV Axis I diagnoses: Schizophrenia, Psychotic
             disorder, Delirium, dementia, amnestic, and other clinically significant cognitive
             disorders, Bipolar or schizoaffective disorder, Cyclothymic disorder, Dissociative
             disorders.

          -  Antisocial or borderline personality disorder.

          -  Serious suicidal risk per the clinical investigator's judgment.
Clinical trial NCT01205932 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (bay59-7939), rivaroxaban (bay59-7939), rivaroxaban (bay59-7939), enoxaparin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 20 years or above

          -  Patients undergoing elective THR (the first replacement of the applicable hip joint)

          -  Patients' written informed consent to participation after receiving detailed verbal
             and written information on any study specific procedures in advance

        Exclusion Criteria:

          -  Planned, staged major orthopedic surgery within 3 months prior to elective THR or
             during this study

          -  History of clinically significant active bleeding (e.g. intracranial bleeding,
             gastrointestinal bleeding*), or high bleeding risk

             *: within 3 months prior to elective THR for gastrointestinal bleeding

          -  Subjects with hepatic disease which is associated with coagulopathy leading to a
             clinically relevant bleeding risk

          -  Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: <30
             mL/min)

          -  Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to
             contrast media)

          -  Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other
             than study medication) that cannot be stopped (in the opinion of the investigator/sub
             investigator)

          -  Subjects for whom epidural catheters are expected to be left in for longer than 18
             hours post-operatively

          -  Planned intermittent pneumatic compression during treatment period
Clinical trial NCT00031798 (phase 3, status: terminated)
Conditions: brain and central nervous system tumors, cognitive/functional effects, depression, fatigue, quality of life
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, R53.83, G93.3, R53.82, R53.0, T67.6XXS, T67.6XXA, T67.6XXD
Drugs: methylphenidate hydrochloride
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Reason stopped: 
    low accrual; loss of funding
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic brain tumor OR

          -  Histologically confirmed primary brain tumor

               -  Glioblastoma multiforme

               -  Anaplastic astrocytoma

               -  Anaplastic oligodendroglioma

               -  Anaplastic mixed oligoastrocytoma

               -  Low-grade glioma

               -  Meningioma

               -  Ependymoma

          -  Planned external beam cranial radiotherapy (partial or whole brain) with a total dose
             of at least 25 Gy in at least 10 fractions of 180-300 cGy each

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC ≥ 1,500/mm^3

          -  Hemoglobin ≥ 10.0 g/dL

          -  Platelet count ≥ 75,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No hypertension or other cardiovascular disease requiring antihypertensives and/or
             other cardiovascular medications

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other serious medical or psychiatric illness that would preclude study
             participation

          -  No hypersensitivity to study drug

          -  No history of steroid psychosis

          -  No family history of or active Tourette's Syndrome

          -  No prior or active glaucoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior or concurrent chemotherapy allowed

        Endocrine therapy:

          -  Concurrent steroids allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  Prior radiotherapy allowed except to brain (including stereotactic radiosurgery)

          -  No concurrent craniospinal axis radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No prior or concurrent medications for attention deficit disorder, anxiety disorder,
             schizophrenia, or substance abuse

          -  No concurrent anti-depressants
Clinical trial NCT00651612 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, concurrent brimonidine 0.2% and 0.5% timolol
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ocular hypertension or glaucoma

          -  Patient requires IOP-lowering therapy in both eyes

        Exclusion Criteria:

          -  Uncontrolled medical conditions

          -  Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
Clinical trial NCT00704509 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: bifeprunox, placebo, quetiapine
SMILES: O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Reason stopped: 
    interim analysis showed inadequate efficacy of bifeprunox
  
Eligibility criteria:

        Inclusion Criteria:

        Main inclusion criteria

          -  The subject has a primary diagnosis of schizophrenia

          -  The subject experiences clinically significant symptoms

          -  The subject's medication remained stable for 8 weeks prior to screening

          -  The subject is currently in the post-acute maintenance phase of his/her disease

        Exclusion Criteria:

        Main exclusion criteria

          -  The subject is at significant risk of suicide

          -  The subject is treatment resistant

          -  The subject has experienced an acute exacerbation within 8 weeks prior screening

          -  The subject is unlikely to comply with the protocol

          -  The subject has a current diagnosis or a history of substance abuse
Clinical trial NCT01187992 (phase 3, status: terminated)
Conditions: acute coronary syndrome, coronary artery disease
ICD codes: I24.0, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Reason stopped: 
    interim analysis showed significant effect in favour of full-dose atorvastatin.
  
Eligibility criteria:

        Inclusion Criteria:

          -  non-ST-segment elevation acute myocardial infarction.

          -  coronary angiography within 48 hours from admission.

          -  angiographic evidence of severe and diffuse coronary artery disease,not amenable to
             conventional direct revascularisation techniques by coronary artery bypass graft
             (CABG) or percutaneous coronary intervention (PCI).

        Exclusion Criteria:

          -  ST-segment elevation acute myocardial infarction,

          -  clinical history of heart failure

          -  left ventricular ejection fraction <35%,

          -  any form of severe valvular dysfunction,

          -  previous implantation or indication to implant a cardioverter-defibrillator during the
             index admission,

          -  any increase in liver enzymes,

          -  history of any liver or muscle disease,

          -  renal failure with serum creatinine >2.5 mg/dL (221 mmol/L),

          -  need for continued use of intravenous medications to relieve anginal symptoms,

          -  presence of any major comorbidity with life expectancy <24 months.
Clinical trial NCT00117338 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, comparator: placebo (unspecified)
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children 6-14 years of age seeking treatment in emergency departments with acute
             asthma attacks

        Exclusion Criteria:

          -  Other respiratory conditions (including congenital lung abnormalities) or other acute
             illnesses that would complicate current treatment and response for asthma
Clinical trial NCT00244608 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol turbuhaler, budesonide turbuhaler (pulmicort), terbutaline turbuhaler
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of asthma for at least 6 months

          -  Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one

        Exclusion Criteria:

          -  Respiratory infection affecting asthma within 30 days prior to study

          -  Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to
             study

          -  Any significant disease or disorder that may jeopardize the safety of the patient
Clinical trial NCT01625494 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: irbesartan/amlodipine (150/5mg), irbesartan/amlodipine (150/10mg), irbesartan/amlodipine (300/5mg), irbesartan/amlodipine (300/10mg)
SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion criteria :

          -  Men and women ≥18 years old

          -  Established essential hypertension

          -  Treated with irbesartan 150 mg or amlodipine 5 mg as monotherapy for at least 2 weeks

          -  With uncontrolled systolic BP (blood pressure) defined as ≥140 mm Hg assessed by OBPM
             (office blood pressure measurements)

          -  Signed written informed consent obtained prior to inclusion to the study

        Exclusion criteria:

          -  Mean systolic BP ≥180 mm Hg and/or mean diastolic BP ≥110 mm Hg by OBPM on Visit 1

          -  Known or suspected causes of secondary hypertension

          -  Patients with bilateral artery stenosis, renal artery stenosis in a solitary kidney,
             renal transplant or only has one functioning kidney

          -  Known contraindications or hypersensitivity to either amlodipine or irbesartan or to
             the combination

          -  History of angioedema related to the administration of an angiotensin II receptor
             antagonist or any combination of the drugs used

          -  Severe hepatic impairment (Alanine aminotransferase (ALT) or Aspartate
             aminotransferase (AST) >5 times the upper normal limit (ULN) or history of hepatic
             encephalopathy, esophageal varices or portocaval shunt)

          -  Severe renal impairment (glomerular filtration rate <30 ml/min)

          -  Concomitant use of any other antihypertensive treatment except of Irbesartan and
             Amlodipine

          -  Administration of any other investigational drug within 30 days before inclusion

          -  Presence of any other conditions that would restrict or limit the patient
             participation for the duration of the study

          -  Pregnant or breast feeding women

          -  Women of childbearing potential unable or unwilling to use an acceptable method to
             avoid pregnancy for the entire study period

          -  Patient is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00207831 (phase 3, status: terminated)
Conditions: rectal cancer, stage ii/iii, t3 or t4 (only anal extension) rectal cancer, n0-2, m0
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: tegafur and uracil
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O
Reason stopped: 
    terminated after interim analysis
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive adenocarcinoma of the rectum , M0, lower side < 10
             cm from anal verge

          -  T3 or T4 disease (T4 exclusive anal extension )

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-2 OR

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin < x2 UNL

        Renal

          -  Creatinine < 150 µMol/L

        Gastrointestinal

          -  No history of inflammatory bowel disease

          -  No history of difficulty or inability to take or absorb oral medications

        Neurologic

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except curatively treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No history of psychiatric conditions or diminished mental capacity that would preclude
             study compliance or giving informed consent

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  No prior chemotherapy

        Radiotherapy

          -  No prior radiotherapy to the pelvis

        Other

          -  No other concurrent investigational drugs

          -  No other concurrent anticancer treatment
Clinical trial NCT00547651 (phase 3, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: amrubicin, topotecan
SMILES: [H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of SCLC at study entry according to the
             International Association for the Study of Lung Cancer (IASLC) histopathologic
             classification. Mixed or combined subtypes according to the IASLC are not allowed;

          -  SCLC that is either sensitive (defined as a response including stable disease to
             first-line platinum-based chemotherapy, with subsequent progression >/= 90 days after
             completing first-line chemotherapy) or refractory (defined as best response to
             first-line platinum-based chemotherapy or progression < 90 days after completing
             first-line chemotherapy);

          -  Extensive or limited disease; patients with limited disease who are candidates for
             local or regional salvage radiation therapy must have been offered such treatment
             prior to participation in this study;

          -  Radiographically documented progression after first-line treatment with platinum-based
             chemotherapy;

          -  No more than 1 prior chemotherapy regimen;

          -  At least 18 years of age;

          -  ECOG performance status of 0 - 1

        Exclusion Criteria:

          -  Chest radiotherapy with curative intent to the primary disease complex </= 28 days
             prior to first dose; CNS radiotherapy </= 21 days prior to first dose; radiotherapy to
             all other areas </= 7 days prior to first dose;

          -  Prior anthracycline, topotecan, or irinotecan treatment.

          -  Prior anthracycline or topotecan treatment.

          -  Patients with know history of seropositive human immunodeficiency virus (HIV) or
             patients who are receiving immunosuppressive medications that would increase the risk
             of serious neutropenic complications
Clinical trial NCT00147381 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: alemtuzumab, tacrolimus, alemtuzumab
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  age 18-65

          -  endstage renal failure with no previous renal transplantation

          -  cadaveric donor

          -  written informed consent

        Exclusion Criteria:

          -  pregnant or nursing women

          -  multi-organ transplant recipients

          -  live donor recipients

          -  re-transplants

          -  panel reactive antibodies (PRA) > 25%

          -  previous treatment with Campath-1H

          -  use of other investigational agents within 6 weeks

          -  active systemic infection

          -  HIV positive patient or donor

          -  positive lymphocyte cytotoxicity cross-match between recipient serum and donor cells

          -  past history of anaphylaxis following exposure to humanized monoclonal antibodies
Clinical trial NCT00250432 (phase 3, status: completed)
Conditions: invasive candidiasis
ICD codes: B37.1, B37.9, P37.5, B37.49, B37.89, B37.2, B37.3
Drugs: caspofungin acetate
SMILES: CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical and Laboratory evidence of blood stream &/or systemic candida infections

        Exclusion Criteria:

          -  Possible candida contamination

          -  Candida colonization (non invasive infection), urine, cardiac, bone or brain and
             prosthetic device infections

          -  Acute or moderately severe liver disease

          -  Abnormal liver function tests

          -  Abnormal blood clotting for patients on blood thinners